BAUSCH HEALTH
LIVE

Serial Number

87953650

Owner

Bausch & Lomb Incorporated

Attorney

Robert J. Gorman

First Use Date

Mar 12, 2014

Filing Date

Jun 8, 2018

Add to watchlist:

No watchlists yet
View on USPTO

BAUSCH HEALTH Trademark

Serial Number: 87953650 • Registration: 6598161

BAUSCH HEALTH is a trademark filed by Bausch & Lomb Incorporated on June 8, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Bausch & Lomb Incorporated (17 trademarks)

1400 N. Goodman Street
Rochester, NY 14609

Entity Type: 03

Trademark Details

Filing Date

June 8, 2018

Registration Date

December 21, 2021

First Use Anywhere

March 12, 2014

First Use in Commerce

March 12, 2014

Published for Opposition

January 29, 2019

Goods & Services

Pharmaceutical preparations, namely, an oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;, namely, diazepam rectal gel; Pharmaceutical preparations for the treatment of cancer, neurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravis, depression, mood/anxiety conditions, solar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the prevention, treatment and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of cardio-pulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension, high blood pressure, heart failure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the prevention, treatment and alleviation of central nervous system disorders, diseases, conditions and ailments, namely, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, cerebral palsy, insomnia, mood disorders, bipolar disorder, seizure disorders; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseases, namely, auto immune motility diseases, immunologic deficiency syndromes, auto immune diseases, Acquired Immune Deficiency Syndrome (AIDS), hypersensitivity, allergies, tumors of the immunological organs; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculoskeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; antiviral pharmaceutical compounds; antiobesity agent in the nature of a pharmaceutical preparation; Dermotherapeutic preparation for use in the treatment of obesity; Pharmaceutical products, namely, lipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; Pharmaceutical preparations, namely, a topical cream for the treatment of pre-cancerous skin lesions; pharmaceutical preparations and substances for the prevention and treatment of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nausea, emesis; Medicines and medicinal preparations for human purposes, namely, to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical preparations and substances for the treatment of epilepsy, seizures and neurological and psychological diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations, namely, immunomodulators; anticholinesterase preparation for the prevention, treatment and alleviation of a neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 14, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 14, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 14, 2026 REAP
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Sep 10, 2025 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jul 25, 2025 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Oct 11, 2023 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 28, 2022 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 21, 2022 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 14, 2022 ASCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 10, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 10, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 10, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 10, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 10, 2022 COAR
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jun 23, 2022 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
May 25, 2022 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Mar 9, 2022 ASCK
REGISTERED-PRINCIPAL REGISTER
Dec 21, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 19, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Nov 18, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Nov 10, 2021 SUPC
USE AMENDMENT FILED
Nov 7, 2021 IUAF
TEAS STATEMENT OF USE RECEIVED
Nov 7, 2021 EISU
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 16, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 16, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 16, 2021 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 10, 2021 EXRA
SOU EXTENSION 5 GRANTED
Sep 9, 2021 EX5G
SOU EXTENSION 5 FILED
Sep 5, 2021 EXT5
SOU TEAS EXTENSION RECEIVED
Sep 5, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 23, 2021 EXRA
SOU EXTENSION 4 GRANTED
Mar 21, 2021 EX4G
SOU EXTENSION 4 FILED
Mar 21, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 21, 2021 EEXT
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Nov 25, 2020 ASCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 29, 2020 EXRA
SOU EXTENSION 3 GRANTED
Sep 25, 2020 EX3G
SOU EXTENSION 3 FILED
Sep 25, 2020 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 25, 2020 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 11, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 11, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 11, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 11, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 11, 2020 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 28, 2020 EXRA
SOU EXTENSION 2 GRANTED
Mar 26, 2020 EX2G
SOU EXTENSION 2 FILED
Mar 26, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 26, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 30, 2019 EXRA
SOU EXTENSION 1 GRANTED
Oct 29, 2019 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 29, 2019 AITU
NOTICE OF REVIVAL - E-MAILED
Sep 30, 2019 NREV
SOU EXTENSION RECEIVED WITH TEAS PETITION
Sep 27, 2019 TPEX
PETITION TO REVIVE-GRANTED
Sep 27, 2019 PETG
TEAS PETITION TO REVIVE RECEIVED
Sep 27, 2019 PROA
SOU EXTENSION 1 FILED
Sep 26, 2019 EXT1
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 26, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 29, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jan 29, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 9, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 22, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 21, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 20, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 20, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 19, 2018 GNRN
NON-FINAL ACTION E-MAILED
Dec 19, 2018 GNRT
NON-FINAL ACTION WRITTEN
Dec 19, 2018 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Dec 11, 2018 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Nov 20, 2018 PBCR
ASSIGNED TO LIE
Nov 2, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 22, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 22, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 22, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 22, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 4, 2018 GNRN
NON-FINAL ACTION E-MAILED
Oct 4, 2018 GNRT
NON-FINAL ACTION WRITTEN
Oct 4, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 22, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 22, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 15, 2018 GNRN
NON-FINAL ACTION E-MAILED
Aug 15, 2018 GNRT
NON-FINAL ACTION WRITTEN
Aug 15, 2018 CNRT
ASSIGNED TO EXAMINER
Aug 15, 2018 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 15, 2018 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 14, 2018 NWOS
NEW APPLICATION ENTERED
Jun 12, 2018 NWAP